Finance

Lists
Why is 600664 up 2,10%?
Dive Deeper
600664:SHA
Harbin Pharmaceutical Group Co Ltd
6,32 CN¥
+2,10%
(+0,13) 1D
16 қаз., 15:00:01 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600664...
Open
6,26 CN¥
High
6,77 CN¥
Low
6,19 CN¥
Mkt. cap
15,92 млрд
Avg. vol.
387,14 млн
Volume
412,40 млн
P/E ratio
31,08
52-wk high
9,86 CN¥
52-wk low
2,84 CN¥
EPS
0,20 CN¥
Shares outstanding
2,54 млрд
No. of employees
10 мың
Open
6,26 CN¥
High
6,77 CN¥
Low
6,19 CN¥
Mkt. cap
15,92 млрд
Avg. vol.
387,14 млн
Volume
412,40 млн
P/E ratio
31,08
52-wk high
9,86 CN¥
52-wk low
2,84 CN¥
EPS
0,20 CN¥
Shares outstanding
2,54 млрд
No. of employees
10 мың
News stories
From web sources and news partners
Profile
Harbin Pharmaceutical Group Co., Ltd. is a Chinese partially state-owned company engaged in the research & development, manufacture, and sale of pharmaceutical products. HPGC medication offerings include traditional Chinese medicine and biopharmaceuticals; its main offerings include antibiotics, including amoxicillin and penicillin, and dietary supplements, including zinc gluconate and calcium gluconate. The company owns both Renmintongtai, a drugstore chain and medical wholesaler for the domestic market, and GNC, a U.S.-based international retailer of supplements and wellness products. Wikipedia
About Harbin Pharmaceutical Group Co Ltd
CEO-
Employees10 мың
Founded1988
Headquarters-
SectorPharmaceutical industry
Websitehayao.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
3,90 млрд
3,94 млрд
4,18 млрд
4,12 млрд
Cost of goods sold
2,95 млрд
2,96 млрд
3,17 млрд
2,96 млрд
Cost of revenue
2,95 млрд
2,96 млрд
3,17 млрд
2,96 млрд
Research and development expenses
33,63 млн
51,31 млн
27,02 млн
33,38 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
753,48 млн
815,96 млн
721,16 млн
803,44 млн
Operating expense
838,57 млн
897,00 млн
786,62 млн
895,87 млн
Total operating expenses
3,78 млрд
3,85 млрд
3,96 млрд
3,86 млрд
Operating income
112,30 млн
88,76 млн
219,91 млн
264,89 млн
Other non operating income
468,22 м.
-13,01 млн
-7,97 млн
1,21 млн
EBT including unusual items
119,12 млн
91,70 млн
206,43 млн
311,43 млн
EBT excluding unusual items
109,94 млн
63,73 млн
208,13 млн
254,28 млн
Income tax expense
41,30 млн
34,62 млн
45,36 млн
63,42 млн
Effective tax rate
34,67%
37,75%
21,97%
20,37%
Other operating expenses
24,67 млн
29,19 млн
21,94 млн
53,95 млн
Net income
68,89 млн
33,00 млн
161,13 млн
249,19 млн
Net profit margin
1,77%
0,84%
3,86%
6,05%
Earnings per share
-
-
-
-
Interest and investment income
4,05 млн
3,14 млн
4,20 млн
6,12 млн
Interest expense
-11,05 млн
-10,76 млн
-8,01 млн
-10,10 млн
Net interest expenses
-7,00 млн
-7,62 млн
-3,81 млн
-3,98 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
166,37 млн
143,03 млн
274,17 млн
320,66 млн
Gain or loss from assets sale
3,99 млн
-3,83 млн
-
-35,83 млн
AI content may include mistakes. Learn more
Google қолданбалары